{"id":390634,"date":"2018-06-29T00:00:00","date_gmt":"2018-06-29T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0004-2018-biopharma-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia-current-treatment-physician-insights-us\/"},"modified":"2026-03-31T10:48:15","modified_gmt":"2026-03-31T10:48:15","slug":"cutron0004-2018-biopharma-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia-current-treatment-physician-insights-us","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0004-2018-biopharma-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia-current-treatment-physician-insights-us\/","title":{"rendered":"Non-Hodgkin&#8217;s Lymphoma and Chronic Lymphocytic Leukemia | Current Treatment: Physician Insights | US | 2018"},"content":{"rendered":"<p><strong>Introduction:<\/strong><\/p>\n<p>Non-Hodgkin\u2019s lymphoma (<abbr data-original-title=\"non-Hodgkin's lymphoma\" title=\"\">NHL<\/abbr>) is a heterogeneous group of malignancies that can be broadly classified into indolent and aggressive subtypes. The treatment algorithm for\u00a0<abbr data-original-title=\"non-Hodgkin's lymphoma\" title=\"\">NHL<\/abbr>\u00a0continues to evolve as drug labels are expanded and new drugs are added to the armamentarium, such as Bayer HealthCare\u2019s Aliqopa, Kite Pharma\/Gilead Sciences\u2019\u00a0<abbr data-original-title=\"chimeric antigen receptor\" title=\"\">CAR<\/abbr>\u00a0T-cell therapy Yescarta, and AstraZeneca\u2019s Calquence. This report provides an in-depth analysis of current treatment practices and drivers of therapy selection for key\u00a0<abbr data-original-title=\"non-Hodgkin's lymphoma\" title=\"\">NHL<\/abbr>\u00a0subtypes, including follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia (<abbr data-original-title=\"chronic lymphocytic leukemia\" title=\"\">CLL<\/abbr>).<\/p>\n<p><strong>Questions answered:<\/strong><\/p>\n<ul>\n<li>What are the current treatment practices for newly diagnosed and relapsed\/refractory\u00a0<abbr data-original-title=\"non-Hodgkin's lymphoma\" title=\"\">NHL<\/abbr>subtypes?<\/li>\n<li>What is the uptake of recent market entrants in the United States, such as Aliqopa and Calquence?<\/li>\n<li>What are the key drivers and obstacles determining current prescribing patterns in\u00a0<abbr data-original-title=\"chronic lymphocytic leukemia\" title=\"\">CLL<\/abbr>?<\/li>\n<li>How do drug-treatment rates vary across\u00a0<abbr data-original-title=\"non-Hodgkin's lymphoma\" title=\"\">NHL<\/abbr>\/<abbr data-original-title=\"chronic lymphocytic leukemia\" title=\"\">CLL<\/abbr>\u00a0subtypes and practice settings?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><em>Current Treatment: Physician Insights<\/em>\u00a0provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so you can create specific messaging around these treatment dynamics in order to more effectively increase or defend your market position.<\/p>\n<p><strong>Markets covered:<\/strong>\u00a0United States<\/p>\n<p><strong>Primary research:\u00a0<\/strong>Survey of 99 U.S. hematologist-oncologists fielded in April 2018.<\/p>\n<p><strong>Key companies:<\/strong>\u00a0AbbVie, Acerta Pharma, AstraZeneca, Bayer HealthCare, Celgene, Genmab, Gilead Sciences, Johnson &#038; Johnson, Kite Pharma, Novartis, Roche\/Genentech, Takeda, Teva<\/p>\n<p><strong>Key drugs:<\/strong>\u00a0Aliqopa, Arzerra, Calqueunce, Gazyva, Imbruvica, Revlimid, Rituxan, Velcade, Venclexta, Yescarta, Zydelig<\/p>\n","protected":false},"template":"","class_list":["post-390634","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hodgkins-lymphoma","biopharma-therapy-areas-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390634","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390634\/revisions"}],"predecessor-version":[{"id":576725,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390634\/revisions\/576725"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390634"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}